Creekmur Asset Management LLC Has $1.39 Million Stock Holdings in Axon Enterprise, Inc $AXON

Creekmur Asset Management LLC lifted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 54.9% during the 2nd quarter, Holdings Channel reports. The firm owned 1,684 shares of the biotechnology company’s stock after purchasing an additional 597 shares during the quarter. Creekmur Asset Management LLC’s holdings in Axon Enterprise were worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of AXON. Jennison Associates LLC increased its stake in shares of Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares during the last quarter. Nuveen LLC acquired a new position in shares of Axon Enterprise during the 1st quarter worth about $264,796,000. McElhenny Sheffield Capital Management LLC acquired a new position in shares of Axon Enterprise during the 2nd quarter worth about $255,833,000. Westfield Capital Management Co. LP increased its stake in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Axon Enterprise news, Director Hadi Partovi bought 1,358 shares of the firm’s stock in a transaction on Wednesday, August 13th. The shares were purchased at an average price of $740.00 per share, for a total transaction of $1,004,920.00. Following the transaction, the director directly owned 237,938 shares in the company, valued at approximately $176,074,120. This trade represents a 0.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the transaction, the insider owned 144,538 shares in the company, valued at approximately $108,417,953.80. The trade was a 5.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 59,932 shares of company stock worth $45,115,616. Insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $738.88 on Friday. The company’s 50 day moving average price is $731.73 and its two-hundred day moving average price is $730.58. Axon Enterprise, Inc has a 12-month low of $422.38 and a 12-month high of $885.91. The firm has a market cap of $58.01 billion, a PE ratio of 182.44, a PEG ratio of 29.49 and a beta of 1.41. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the prior year, the business posted $1.20 EPS. The business’s revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AXON. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Wolfe Research started coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating on the stock. Northland Securities set a $800.00 price target on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.